Anteris Technologies Global

AVR · NASDAQ

$6.29+$0.11 (+1.78%)TodayMarket closed · Oct 20, 7:35 PM ET

Prev close $6.18

AVR analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 5 analysts

Average $15.05 (+139.2% upside)

Low: $13.13
Now: $6.29
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

AVR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Oct 14, 2026	Maintains	Overweight	$15.00	57%
Barclays	Oct 7, 2026	Initiates	Equal-Weight	$10.00	57%
Cantor Fitzgerald	Aug 14, 2026	Maintains	Overweight	$15.00	57%
Barclays	May 15, 2026	Maintains	Overweight	$17.00 → $18.00	57%
Cantor Fitzgerald	Mar 27, 2026	Maintains	Overweight	$15.00	57%
Cantor Fitzgerald	Mar 12, 2026	Initiates	Overweight	$15.00	57%
Wells Fargo	Mar 11, 2026	Initiates	Overweight	$16.00	54%

The case for and against

Updated Oct 16, 2026

Bull case

Anteris Technologies Glb is viewed positively because DurAVR’s physician-led, biomimetic single-piece design appears mechanically differentiated in ways that could translate into superior hemodynamics, including peer platforms exceeding 40%+ PPM in small annuli versus just 3% for DurAVR and mean gradients in the low 8s versus competitors in the low-to-mid teens. The PARADIGM trial’s ~1,054-patient head-to-head structure, expanding enrollment in the United States and France, and a valve-in-valve registry enrolling ahead of plan all support a credible pathway to validate that differentiation in a large market. Financially, the company ended 2Q26 with $260.9M of cash, grew R&D 34% Q/Q to $23.4M, and is investing in manufacturing and clinical scale-up, reinforcing execution capacity and long-term growth potential.

Bear case

Anteris Technologies Glb is burdened by a structurally difficult market in which only 15% to 20% of severe aortic stenosis patients are treated today, even though the disease is fatal in roughly half of untreated patients within two years, underscoring that adoption depends on overcoming both diagnostic limitations and skepticism toward current technology. Its outlook is further weakened by major execution risks around PARADIGM trial outcomes and the possibility that FDA PMA approval takes longer than it is capitalized for, creating a real funding and commercialization overhang. The company’s significant operating losses and negative cash flow, combined with no proven marketing or sales strategy for DurAVR, raise the risk that expenses outpace resources before meaningful market acceptance is achieved.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.